Back to results
US 8,034,834 B2Granted
Method for treating proliferative disorders with HSP90 inhibitors
AssigneeSynta Pharmaceuticals Corp.
InventorsZhenjian Du, Kevin Foley
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating Bcr-Abl, FLT-3, EGFR, c-Kit, B-raf, and NPM-ALK associated cancers, in a subject in need thereof.
Claims15
A method of treating an EGFR associated cancer in a subject, comprising administering to the subject an effective amount of a compound represented by the following formula:
- or a tautomer or pharmaceutically acceptable salt thereof, wherein:
- X45 is CR54;
- Z1 is —OH or —SH;
- R52 is selected from the group consisting of —H, methyl, ethyl, n-propyl, isopropyl, n-butyl, n-pentyl, n-hexyl, —(CH2)2OCH3, —CH2C(O)OH, and —C(O)N(CH3)2;
- R53 is —H, methyl, ethyl, or isopropyl;
- R54 is —H or a lower alkyl;
- R55 is selected from the group consisting of —H, —OH, —OCH3, and —OCH2CH3;
- and
- R56 is selected from the group consisting of —H, methyl, ethyl, isopropyl, and cyclopropyl.
6 more elements
A method of inducing degradation of EGFR in a subject, comprising administering to the subject an effective amount of a compound represented by the following formula:
- or a tautomer and/or pharmaceutically acceptable salt thereof, wherein:
- X45 is CR54;
- Z1 is —OH or —SH;
- R52 is selected from the group consisting of —H, methyl, ethyl, n-propyl, isopropyl, n-butyl, n-pentyl, n-hexyl, —(CH2)2OCH3, —CH2C(O)OH, and —C(O)N(CH3)2;
- R53 is —H, methyl, ethyl, or isopropyl;
- R54 is —H or a lower alkyl;
- R55 is selected from the group consisting of —H, —OH, —OCH3, and —OCH2CH3;
- and
- R56 is selected from the group consisting of —H, methyl, ethyl, isopropyl, and cyclopropyl.
6 more elements
Dependencies are inferred from the claim text.